Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease-Reference-Cited by-同舟云学术

Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease

Published:2024-04-29 Issue:6 Volume:19 Page:639-647
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Lozupone Madia¹^ORCID,Dibello Vittorio²³^ORCID,Sardone Rodolfo⁴,Castellana Fabio²,Zupo Roberta²,Lampignano Luisa⁵,Bortone Ilaria⁵,Stallone Roberta⁶,Altamura Mario⁷,Bellomo Antonello⁷,Daniele Antonio⁸⁹,Solfrizzi Vincenzo²,Panza Francesco²^ORCID

Affiliation:

1. Department of Translational Biomedicine and Neuroscience “DiBraiN”, University of Bari Aldo Moro, Bari, Italy

2. Dipartimento Interdisciplinare di Medicina, Clinica Medica e Geriatria “Cesare Frugoni”, University of Bari Aldo Moro, Bari, Italy

3. Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

4. Unit of Statistics and Epidemiology, Local Health Authority of Taranto, Taranto, Italy

5. Local Healthcare Authority of Bari, ASL Bari, Bari, Italy

6. Neuroscience and Education, Human Resources Excellence in Research, University of Foggia, Foggia, Italy

7. Psychiatric Unit, Department of Clinical & Experimental Medicine, University of Foggia, Foggia, Italy

8. Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy

9. Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy

Funder

Development of an ensemble learning-based, multi-dimensional sensory impairment score to predict cognitive impairment in an elderly cohort of Southern Italy

the European Union – Next Generation EU – NRRP M6C2 – Investment 2.1 Enhancement and Strengthening Biomedical Research within the NHS

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2024.2348142

Reference70 articles.

1. Alzheimer's disease

2. 2023 Alzheimer's disease facts and figures

3. Immunotherapy for Alzheimer’s disease: hoops and hurdles

4. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

5. Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?;Diseases;2024-05-22